Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Priority Review Designations In US: Third Quarter Spike Continues In 2017

Executive Summary

Third quarter saw record total of 26 announcements for priority review designations; drop-off now likely.


Related Content

Breakthrough, Priority Review Designations Could Set High-Water Marks In 2018
Breakthrough Therapy Designations Set Quarterly Record
US FDA Sets Records With Breakthrough Therapy, Priority Review Designations In 2017
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
NME Mid-Year Report: Approvals Might Near Record With Strong 2nd Half
Novel Approvals Were Fewer But Faster At US FDA In 2016


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts